1.
Open Forum Infect Dis
; 11(5): ofae263, 2024 May.
Article
de Anglais
| MEDLINE
| ID: mdl-38798896
RÉSUMÉ
Data on posaconazole serum levels of patients on prophylaxis with delayed-release tablets or oral suspension during intensive chemotherapy for acute myeloid leukemia and myelodysplastic syndrome are scarce. In this analysis, the proportion of patients with acute myeloid leukemia/myelodysplastic syndrome achieving posaconazole target concentrations with delayed-release tablets was higher than with oral suspension.